$35.440
-0.138 (-0.39%)收盤時
AVLN 同業比較
In the context of the broader market, AVLN competes directly with industry leaders such as LBRX and LTGO. With a market capitalization of $1.58B, it holds a leading position in the sector. When comparing efficiency, AVLN's gross margin of N/A stands against LBRX's N/A and LTGO's N/A. Such benchmarking helps identify whether Avalyn Pharma Inc is trading at a premium or discount relative to its financial performance.
Avalyn Pharma Inc 財務表現
Avalyn Pharma has reported increasing net losses, with Q2 2026 showing a net loss of $28.9 million, and a current ratio of 33.12, indicating strong liquidity to cover short-term liabilities.
Financials
FY2026Q2
YoY:
+43.68%
-31.29M
Operating Profit
FY2026Q2
YoY:
+43.31%
-28.93M
Net Income after Tax
FY2026Q2
YoY:
+104.17%
-0.98
EPS - Diluted
FY2026Q2
-26.34M
Free Cash Flow
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。